摘要
全球新型冠状病毒肺炎(简称“新冠肺炎”)病例累计>6亿,死亡人数>600万,病死率为1.24%;中国香港第5波疫情有1/6的人感染,每万人死亡15人。以中国香港第5波疫情Omicron变异株1/6的人感染、0.76%死亡率和每年1波疫情来推算,中国实施“动态清零”3年就避免了6990万人的感染和626万人的死亡。随着病毒传染性增强及变异的加速,已观察不到新冠肺炎变异株超长潜伏期。我国对本土局部暴发疫情后的物理围堵隔离措施更为成熟,社会面“动态清零”更快、需时更短,维护了人民的健康和生命安全。根据Delta株传播率,推测新冠肺炎原始株潜伏期分别为≤4 d、≤7 d及≥8 d的构成情况,根据江苏省扬州市疫情部分病例和北京市小金阁服装店关联传播链疫情病例,统计Delta变异株和Omicron变异株潜伏期构成情况,分析对2022年7月广西壮族自治区北海市和崇左市Omicron变异株疫情处置中社会面“清零”的方法与效果。
COVID-19 has caused more than 600 million cases,more than 6 million death and mortality of 1.24%worldwide.One out of every six people caught COVID-19 at the 5th wave of expansion,having a mortality of 15 per 10 thousand.China mainland with the dynamic zeroCOVID-19 strategy have decreased 699 million cases and 6.26 million deaths from dynamic zero-COVID-19 strategy in 3 years in case of yearly outbreak of COVID-19,according to the situation of Omicron variant in Hongkong with incidence of one out of every six people and 0.76%of mortality.With the stronger contagious and variation of the virus,there is less long-term latency.The Chinese governments have more efficient control of epidemic of dynamic zero-COVID-19 strategy caused by imported cases with local diffusion by physical separation and isolation as measure of quarantines;have quick and effective results with zero new cases,which kept the health and safety for people in China.The paper analyzes the efficient measures and achievement of dynamic zero-COVID-19 strategy in Beihai and Chongzuo of Guangxi under the outbreaks of COVID-19 Omicron variant on July of 2022,after the calculation of expanding latency as≤4 days,≤7 days or≥8 days’different latency of primary strains,of expanding latency of Delta variant in part of cases in Yangzhou City of Jiangsu,and of expanding latency of Omicron coming out from chain-expanding cases from Xiaojinge clothing store of Beijing.
作者
卓家同
ZHUO Jiatong(Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention,Nanning,Guangxi 530028,China)
出处
《上海预防医学》
CAS
2022年第12期1257-1260,共4页
Shanghai Journal of Preventive Medicine